GB2600384A - Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia - Google Patents
Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia Download PDFInfo
- Publication number
- GB2600384A GB2600384A GB2015536.2A GB202015536A GB2600384A GB 2600384 A GB2600384 A GB 2600384A GB 202015536 A GB202015536 A GB 202015536A GB 2600384 A GB2600384 A GB 2600384A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- hht
- treatment
- subject
- telangiectasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| IL301466A IL301466A (en) | 2020-09-30 | 2021-09-29 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation |
| KR1020237014688A KR20230080448A (ko) | 2020-09-30 | 2021-09-29 | 유전성 출혈성 모세혈관확장증의 치료에 사용하기 위한 알로스테릭 akt 저해제 |
| US18/247,261 US12466839B2 (en) | 2020-09-30 | 2021-09-29 | Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia |
| JP2023519016A JP7900827B2 (ja) | 2020-09-30 | 2021-09-29 | 遺伝性出血性毛細血管拡張症の治療における使用のためのアロステリックakt阻害剤 |
| MX2023002996A MX2023002996A (es) | 2020-09-30 | 2021-09-29 | Inhibidores alostéricos de akt para su uso en el tratamiento de la telangiectasia hemorrágica hereditaria. |
| CA3192433A CA3192433A1 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| EP21789616.6A EP4221713A1 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| CN202180066598.2A CN116419924A (zh) | 2020-09-30 | 2021-09-29 | 用于治疗遗传性出血性毛细血管扩张症的变构akt抑制剂 |
| PCT/EP2021/076811 WO2022069552A1 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| BR112023004885A BR112023004885A2 (pt) | 2020-09-30 | 2021-09-29 | Composto de fórmula (i), ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de telangiectasia hemorrágica hereditária (hht) em um indivíduo e composto para uso |
| AU2021352108A AU2021352108B2 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| CL2023000926A CL2023000926A1 (es) | 2020-09-30 | 2023-03-29 | Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202015536D0 GB202015536D0 (en) | 2020-11-11 |
| GB2600384A true GB2600384A (en) | 2022-05-04 |
Family
ID=73197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2015536.2A Withdrawn GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12466839B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4221713A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7900827B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230080448A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116419924A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021352108B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004885A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192433A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023000926A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2600384A (cg-RX-API-DMAC7.html) |
| IL (1) | IL301466A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002996A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022069552A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2026038045A1 (en) | 2024-08-15 | 2026-02-19 | Almac Discovery Limited | Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011077098A1 (en) * | 2009-12-23 | 2011-06-30 | Almac Discovery Limited | Inhibitors of akt activity |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| JP2008524339A (ja) | 2004-12-15 | 2008-07-10 | メルク エンド カムパニー インコーポレーテッド | Akt活性のインヒビター |
| WO2006135627A2 (en) | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| EP2120951A4 (en) | 2006-12-06 | 2012-02-15 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| JP2011522047A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
| US8207169B2 (en) | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| EP2116237A1 (en) | 2008-08-05 | 2009-11-11 | Polichem SA | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| US8957064B2 (en) | 2009-02-13 | 2015-02-17 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| MX336865B (es) | 2011-04-07 | 2016-02-04 | Bayer Pharma AG | Imidazopiridazinas como inhibidores de quinasa akt. |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| EP3678666B1 (en) | 2017-09-07 | 2025-07-09 | Augusta University Research Institute, Inc. | Specific akt3 activator and uses thereof |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
-
2020
- 2020-09-30 GB GB2015536.2A patent/GB2600384A/en not_active Withdrawn
-
2021
- 2021-09-29 KR KR1020237014688A patent/KR20230080448A/ko active Pending
- 2021-09-29 CA CA3192433A patent/CA3192433A1/en active Pending
- 2021-09-29 CN CN202180066598.2A patent/CN116419924A/zh active Pending
- 2021-09-29 JP JP2023519016A patent/JP7900827B2/ja active Active
- 2021-09-29 US US18/247,261 patent/US12466839B2/en active Active
- 2021-09-29 EP EP21789616.6A patent/EP4221713A1/en active Pending
- 2021-09-29 IL IL301466A patent/IL301466A/en unknown
- 2021-09-29 BR BR112023004885A patent/BR112023004885A2/pt unknown
- 2021-09-29 WO PCT/EP2021/076811 patent/WO2022069552A1/en not_active Ceased
- 2021-09-29 AU AU2021352108A patent/AU2021352108B2/en active Active
- 2021-09-29 MX MX2023002996A patent/MX2023002996A/es unknown
-
2023
- 2023-03-29 CL CL2023000926A patent/CL2023000926A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011077098A1 (en) * | 2009-12-23 | 2011-06-30 | Almac Discovery Limited | Inhibitors of akt activity |
Non-Patent Citations (4)
| Title |
|---|
| Circulation, vol. 138, 2018, Ola et al. "SAMD4 prevents flow induced arteriovenous malformations by inhibiting casein kinase 2", pages 2379-2394 [Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.033842] * |
| Nature Cell Biology, vol. 19, No. 6, 2017, Jin et al. "Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling", pages 639-652, [Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467724/] * |
| Nature Communications, vol. 7, No. 13650, 2016, Ola et al. "PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia", pages 1-12, [Available from: https://www.nature.com/articles/ncomms13650] * |
| The Journal of Clinical Investigation, vol. 130, No. 2, 2020, Ruiz et al. "Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models", pages 942-957, [Available from https://www.jci.org/articles/view/127425] * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021352108A9 (en) | 2024-05-23 |
| EP4221713A1 (en) | 2023-08-09 |
| MX2023002996A (es) | 2023-05-03 |
| CN116419924A (zh) | 2023-07-11 |
| CL2023000926A1 (es) | 2023-11-03 |
| JP2023543993A (ja) | 2023-10-19 |
| US20240092801A1 (en) | 2024-03-21 |
| CA3192433A1 (en) | 2022-04-07 |
| JP7900827B2 (ja) | 2026-08-05 |
| BR112023004885A2 (pt) | 2023-04-18 |
| GB202015536D0 (en) | 2020-11-11 |
| US12466839B2 (en) | 2025-11-11 |
| AU2021352108B2 (en) | 2026-04-02 |
| AU2021352108A1 (en) | 2023-05-11 |
| WO2022069552A1 (en) | 2022-04-07 |
| KR20230080448A (ko) | 2023-06-07 |
| IL301466A (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5808793B2 (ja) | キナーゼ調節のための化合物および方法、ならびにそれらの適応症 | |
| CA2903293C (en) | Heterocyclic compounds and uses thereof | |
| JP6318156B2 (ja) | キナーゼをモジュレートするための化合物および方法、ならびにその指標 | |
| EP2935248B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| KR102638253B1 (ko) | C5a 억제제로서의 6-5 융합 고리 | |
| AU2016226468A1 (en) | TGF-beta inhibitors | |
| AU2024290864A1 (en) | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof | |
| KR20240135655A (ko) | Rho 관련 단백질 키나아제(rock) 조절제 | |
| AU2021352108B2 (en) | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | |
| WO2022023341A1 (en) | Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof | |
| CA2948582A1 (en) | Carboxamide derivatives | |
| BR112019012920A2 (pt) | amidas aromáticas de ácido carboxílico como antagonistas do receptor b1 de bradicinina | |
| WO2022112493A1 (en) | Phthalazine derivatives as p2x3 inhibitors | |
| WO2007121662A1 (en) | Diphenyl urea derivatives as kinase inhibitors, compositions and uses thereof | |
| WO2021004482A1 (zh) | 取代的吡唑并喹唑啉酮化合物及其应用 | |
| EP4463458A1 (en) | Bicyclic triazine derivatives for the treatment of cancer | |
| EA049324B1 (ru) | Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии | |
| JPWO2008020606A1 (ja) | 血管新生阻害剤 | |
| KR20250148664A (ko) | 디하이드로벤즈이미다졸론 코어를 갖는 ddr1 및 ddr2 억제제 | |
| BR112020013759B1 (pt) | Compostos de triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho, composição farmacêutica compreendendo os referidos compostos e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |